Cargando…

No free lunch—the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI

Detalles Bibliográficos
Autores principales:	Valgimigli, Marco, Gragnano, Felice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210164/ https://www.ncbi.nlm.nih.gov/pubmed/32395560 http://dx.doi.org/10.21037/atm.2020.01.26

Ejemplares similares

Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal
por: Galli, Mattia, et al.
Publicado: (2020)

The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019)

The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE‐DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
por: Eccleston, David S., et al.
Publicado: (2021)

Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis
por: Altoukhi, Renad M, et al.
Publicado: (2020)

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
por: Brunetti, Natale Daniele, et al.
Publicado: (2018)

Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study
por: Valle, Felipe H., et al.
Publicado: (2021)

The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
por: Liu, Zhengwang, et al.
Publicado: (2022)

Still No Free Lunches: The Price to Pay for Tighter PAC-Bayes Bounds
por: Guedj, Benjamin, et al.
Publicado: (2021)

A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
por: Giubilato, Simona, et al.
Publicado: (2022)

Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy
por: Gruttemeier, Julia, et al.
Publicado: (2021)

Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis
por: Goette, Andreas, et al.
Publicado: (2020)

Despise the free lunch
por: Almadi, Majid A, et al.
Publicado: (2021)

A call for action in bleeding prevention
por: Gragnano, Felice, et al.
Publicado: (2019)

The use of antithrombotics in patients presenting with stroke and atrial fibrillation
por: Burgess, Carl, et al.
Publicado: (2007)

Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
por: Abcede, Hermelinda G., et al.
Publicado: (2010)

Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation
por: Bang, Oh Young, et al.
Publicado: (2022)

Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community
por: Joosten, L. P. T., et al.
Publicado: (2022)

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)

Pharmaceutical Patient Assistance Programs: Don't Look a Gift Horse in the Mouth or There's No Such Thing as a Free Lunch
por: Carroll, Norman V.
Publicado: (2007)

Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
por: Jacobs, M. S., et al.
Publicado: (2018)

Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI
por: Schäfer, Andreas, et al.
Publicado: (2020)

Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?
por: Brunetti, Natale Daniele, et al.
Publicado: (2020)

Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis
por: Zhu, Wengen, et al.
Publicado: (2017)

Safety and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: A meta-analysis
por: Moustafa, Abdelmoniem, et al.
Publicado: (2020)

Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
por: Gargiulo, Giuseppe, et al.
Publicado: (2020)

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice
por: Sabir, Ian N, et al.
Publicado: (2013)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
por: Wei, Lili, et al.
Publicado: (2020)

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
por: Bor, Wilbert, et al.
Publicado: (2020)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Moustafa, Abdelmoniem, et al.
Publicado: (2019)

Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2022)

Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions
por: Aloia, Elio, et al.
Publicado: (2019)

Purchasing Behavior, Setting, Pricing, Family: Determinants of School Lunch Participation
por: Sobek, Carolin, et al.
Publicado: (2021)

Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
por: Limbruno, Ugo, et al.
Publicado: (2020)

Antithrombotic therapy in COVID-19
por: Saeed, Sahrai, et al.
Publicado: (2021)

Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
por: Berteotti, M., et al.
Publicado: (2023)

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
por: Suárez Fernández, Carmen, et al.
Publicado: (2015)

Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease
por: Chan, Pak Hei, et al.
Publicado: (2015)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3g1jav9dj43dcospflsbh2ek41